Article Sidebar

PDF (Tiếng Việt)
Published: 2023-10-30
Abstract Views: 175
Views PDF (Tiếng Việt): 173
DOI: https://doi.org/10.52852/tcncyh.v170i9.1870
Issue
Vol. 170 No. 9 (2023)
Section
Các bài báo
How to Cite
Quỳnh, N. T. N., Tranh, Đàm Đình, Hằng, Đinh T. T., & Tùng, T. T. (2023). 35. Evaluation effect of An Nguyet Khang tablet on uterine smooth muscle in the experiment. Journal of Medical Research, 170(9), 313-324. https://doi.org/10.52852/tcncyh.v170i9.1870

35. Evaluation effect of An Nguyet Khang tablet on uterine smooth muscle in the experiment

Nguyen Thi Nhu Quynh, Dam Dinh Tranh, Dinh Thi Thu Hang, Tran Thanh Tung

Main Article Content

Abstract

The study was conducted to evaluate the effect of An Nguyet Khang tablets on uterine smooth muscle. The effect of An Nguyet Khang tablets on uterine smooth muscle was evaluated in an isolated uterus model in Wistar rats and an oxytocin-induced dysmenorrhea model in Swiss mice. The result on isolated rat uterine model showed that An Nguyet Khang tablets at both doses of 132.4 mL/100ml Tyrod and 264.8 mg/100ml Tyrod significantly reduced the frequency and amplitude of uterine contractions. With dysmenorrhea model-caused oxytocin in Swiss mice, An Nguyet Khang tablets with both doses of 1.3 g/kg/day and 2.6 g/kg/day taken continuously for 7 days tend to reduce abdominal pain. Thus, An Nguyet Khang tablets derived from medicinal herbs show a reduction of uterine smooth muscle contraction and consequently relieve pain due to uterine contraction in the isolated uterine model and dysmenorrhea model.

Article Details

Keywords

An Nguyet Khang tablets, dysmenorrhea, uterine smooth muscle

References

1. Primary Dysmenorrhea Consensus Guideline. J Obstet Gynaecol Can. 2005; 27(12): 1117-1130.
2. Guimarães I, Póvoa AM. Primary Dysmenorrhea: Assessment and Treatment. Rev Bras Ginecol E Obstet Rev Fed Bras Soc Ginecol E Obstet. 2020; 42(8): 501-507.
3. Nagy H, Khan MA. Dysmenorrhea. In: StatPearls. StatPearls Publishing; 2023. Accessed September 8, 2023.
4. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014; 36: 104-113.
5. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006; 108(2): 428-441.
6. Sharghi M, Mansurkhani SM, Larky DA, et al. An update and systematic review on the treatment of primary dysmenorrhea. JBRA Assist Reprod. 2019; 23(1): 51-57.
7. Pellow J, Nienhuis C. Medicinal plants for primary dysmenorrhoea: A systematic review. Complement Ther Med. 2018; 37: 13-26.
8. Li Z, Wang L, Cong Y, et al. Flucrypyrim, a novel uterine relaxant, has antinociceptive and anti-inflammatory effects in vivo. Sci Rep. 2017; 7: 42040.
9. YANG L, CAO Z, YU B, CHAI C. An in vivo mouse model of primary dysmenorrhea. Exp Anim. 2015; 64(3): 295-303.
10. Chen Y, Li N, Wang D, Fan J, Chu R, Li S. Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea. J Vis Exp JoVE. 2022; (190).
11. Xie Q, Zhang L, Xie L, et al. Z-ligustilide: A review of its pharmacokinetics and pharmacology. Phytother Res PTR. 2020; 34(8): 1966-1991.